Preclinical autoimmune disease biotech Design Therapeutics files for a $100 million IPO

Design Therapeutics, a preclinical biotech developing gene targeted chimeras for nucleotide expansion diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

Design Therapeutics is a preclinical-stage biopharmaceutical company pioneeringRead More